VanEck Vectors Biotech ETF Competitors

PIMCO Corporate & Income Opportunity Fund (NYSE:PTY) and VanEck Vectors Biotech ETF (NASDAQ:BBH) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Institutional and Insider Ownership

6.9% of PIMCO Corporate & Income Opportunity Fund shares are held by institutional investors. Comparatively, 28.1% of VanEck Vectors Biotech ETF shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Dividends

PIMCO Corporate & Income Opportunity Fund pays an annual dividend of $1.56 per share and has a dividend yield of 8.3%. VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and has a dividend yield of 0.3%. PIMCO Corporate & Income Opportunity Fund has increased its dividend for 1 consecutive years. PIMCO Corporate & Income Opportunity Fund is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of current ratings for PIMCO Corporate & Income Opportunity Fund and VanEck Vectors Biotech ETF, as reported by MarketBeat.com.

Earnings and Valuation

This table compares PIMCO Corporate & Income Opportunity Fund and VanEck Vectors Biotech ETF's gross revenue, earnings per share and valuation.

Profitability

This table compares PIMCO Corporate & Income Opportunity Fund and VanEck Vectors Biotech ETF's net margins, return on equity and return on assets.

Volatility and Risk

PIMCO Corporate & Income Opportunity Fund has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, VanEck Vectors Biotech ETF has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

VanEck Vectors Biotech ETF (NASDAQ:BBH) and Goldman Sachs BDC (NYSE:GSBD) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional and Insider Ownership

28.1% of VanEck Vectors Biotech ETF shares are owned by institutional investors. Comparatively, 13.8% of Goldman Sachs BDC shares are owned by institutional investors. 0.3% of Goldman Sachs BDC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dividends

VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and has a dividend yield of 0.3%. Goldman Sachs BDC pays an annual dividend of $1.80 per share and has a dividend yield of 9.3%. Goldman Sachs BDC pays out 90.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Goldman Sachs BDC has raised its dividend for 1 consecutive years. Goldman Sachs BDC is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for VanEck Vectors Biotech ETF and Goldman Sachs BDC, as provided by MarketBeat.

Goldman Sachs BDC has a consensus target price of $15.9167, indicating a potential downside of 17.91%. Given Goldman Sachs BDC's higher possible upside, analysts plainly believe Goldman Sachs BDC is more favorable than VanEck Vectors Biotech ETF.

Valuation and Earnings

This table compares VanEck Vectors Biotech ETF and Goldman Sachs BDC's revenue, earnings per share (EPS) and valuation.

Goldman Sachs BDC has higher revenue and earnings than VanEck Vectors Biotech ETF.

Profitability

This table compares VanEck Vectors Biotech ETF and Goldman Sachs BDC's net margins, return on equity and return on assets.

Volatility and Risk

VanEck Vectors Biotech ETF has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Goldman Sachs BDC has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Summary

Goldman Sachs BDC beats VanEck Vectors Biotech ETF on 10 of the 12 factors compared between the two stocks.

VanEck Vectors Biotech ETF (NASDAQ:BBH) and Hercules Capital (NYSE:HTGC) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional and Insider Ownership

28.1% of VanEck Vectors Biotech ETF shares are owned by institutional investors. Comparatively, 28.9% of Hercules Capital shares are owned by institutional investors. 3.3% of Hercules Capital shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dividends

VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and has a dividend yield of 0.3%. Hercules Capital pays an annual dividend of $1.28 per share and has a dividend yield of 7.6%. Hercules Capital pays out 90.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hercules Capital has raised its dividend for 1 consecutive years. Hercules Capital is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for VanEck Vectors Biotech ETF and Hercules Capital, as provided by MarketBeat.

Hercules Capital has a consensus target price of $13.8438, indicating a potential downside of 18.08%. Given Hercules Capital's higher possible upside, analysts plainly believe Hercules Capital is more favorable than VanEck Vectors Biotech ETF.

Valuation and Earnings

This table compares VanEck Vectors Biotech ETF and Hercules Capital's revenue, earnings per share (EPS) and valuation.

Hercules Capital has higher revenue and earnings than VanEck Vectors Biotech ETF.

Profitability

This table compares VanEck Vectors Biotech ETF and Hercules Capital's net margins, return on equity and return on assets.

Volatility and Risk

VanEck Vectors Biotech ETF has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Hercules Capital has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Summary

Hercules Capital beats VanEck Vectors Biotech ETF on 11 of the 12 factors compared between the two stocks.

VanEck Vectors Biotech ETF (NASDAQ:BBH) and Royce Value Trust (NYSE:RVT) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional and Insider Ownership

28.1% of VanEck Vectors Biotech ETF shares are owned by institutional investors. Comparatively, 24.6% of Royce Value Trust shares are owned by institutional investors. 0.5% of Royce Value Trust shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dividends

VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and has a dividend yield of 0.3%. Royce Value Trust pays an annual dividend of $1.02 per share and has a dividend yield of 5.5%.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for VanEck Vectors Biotech ETF and Royce Value Trust, as provided by MarketBeat.

Valuation and Earnings

This table compares VanEck Vectors Biotech ETF and Royce Value Trust's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares VanEck Vectors Biotech ETF and Royce Value Trust's net margins, return on equity and return on assets.

Volatility and Risk

VanEck Vectors Biotech ETF has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Royce Value Trust has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.

Summary

Royce Value Trust beats VanEck Vectors Biotech ETF on 3 of the 4 factors compared between the two stocks.

VanEck Vectors Biotech ETF (NASDAQ:BBH) and The Gabelli Equity Trust (NYSE:GAB) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional and Insider Ownership

28.1% of VanEck Vectors Biotech ETF shares are owned by institutional investors. Comparatively, 5.6% of The Gabelli Equity Trust shares are owned by institutional investors. 1.0% of The Gabelli Equity Trust shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dividends

VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and has a dividend yield of 0.3%. The Gabelli Equity Trust pays an annual dividend of $0.60 per share and has a dividend yield of 8.6%. The Gabelli Equity Trust has raised its dividend for 1 consecutive years. The Gabelli Equity Trust is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for VanEck Vectors Biotech ETF and The Gabelli Equity Trust, as provided by MarketBeat.

Valuation and Earnings

This table compares VanEck Vectors Biotech ETF and The Gabelli Equity Trust's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares VanEck Vectors Biotech ETF and The Gabelli Equity Trust's net margins, return on equity and return on assets.

Volatility and Risk

VanEck Vectors Biotech ETF has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, The Gabelli Equity Trust has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Summary

The Gabelli Equity Trust beats VanEck Vectors Biotech ETF on 4 of the 5 factors compared between the two stocks.

VanEck Vectors Biotech ETF (NASDAQ:BBH) and Tri-Continental (NYSE:TY) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.

Risk & Volatility

VanEck Vectors Biotech ETF has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Tri-Continental has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VanEck Vectors Biotech ETF and Tri-Continental, as provided by MarketBeat.com.

Profitability

This table compares VanEck Vectors Biotech ETF and Tri-Continental's net margins, return on equity and return on assets.

Dividends

VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and has a dividend yield of 0.3%. Tri-Continental pays an annual dividend of $1.62 per share and has a dividend yield of 4.8%.

Institutional and Insider Ownership

28.1% of VanEck Vectors Biotech ETF shares are held by institutional investors. Comparatively, 8.8% of Tri-Continental shares are held by institutional investors. 8.7% of Tri-Continental shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares VanEck Vectors Biotech ETF and Tri-Continental's revenue, earnings per share (EPS) and valuation.

Summary

Tri-Continental beats VanEck Vectors Biotech ETF on 3 of the 4 factors compared between the two stocks.